Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin Labs, a specialty pharmaceutical company, has signed an agreement with GlaxoSmithKline and Glaxo Group that appoints Paladin Labs as the exclusive distributor of Dexedrine within Canada for a period of three years, with an option for Paladin to purchase all remaining rights to the product in Canada at the end of that period.
Subscribe to our email newsletter
GlaxoSmithKline (GSK) will be providing certain distribution support services for an interim period. The agreement also marks the start of a strategic relationship with GSK whereby Paladin Labs will have the first right to partner with GSK on a number of products that GSK may choose to license or divest in Canada. Financial terms of the transaction were not disclosed.
Dexedrine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and in the adjunctive treatment of narcolepsy.
Jonathan Goodman, president and CEO of Paladin Labs, said: This agreement will allow us to add to our portfolio of specialty pharmaceutical products and to build significant critical mass for our organization. Not only will we be adding close to $14 million to our top line next year, but just as importantly, we are establishing a strategic relationship with GSK for potential future transactions like this one.